BLIS Technologies Ltd
NZX:BLT

Watchlist Manager
BLIS Technologies Ltd Logo
BLIS Technologies Ltd
NZX:BLT
Watchlist
Price: 0.015 NZD -6.25% Market Closed
Market Cap: 19.2m NZD
Have any thoughts about
BLIS Technologies Ltd?
Write Note

Operating Margin
BLIS Technologies Ltd

12.9%
Current
-9%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.9%
=
Operating Profit
1.6m
/
Revenue
12.7m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NZ
BLIS Technologies Ltd
NZX:BLT
19.2m NZD
13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
755.8B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
351.1B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.8B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
151.5B USD
22%
Country NZ
Market Cap 19.2m NZD
Operating Margin
13%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 755.8B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 351.1B USD
Operating Margin
28%
Country US
Market Cap 251.8B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

BLIS Technologies Ltd
Glance View

Market Cap
19.2m NZD
Industry
Pharmaceuticals

BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce Bacteriocin activity. The company is headquartered in Dunedin, Otago. The company went IPO on 2001-07-30. The firm is also engaged in supply of healthcare ingredients and the manufacture of part and finished goods and food products for sale in domestic and international markets. The firm supplies BLIS-branded finished goods. The firm's products include BLIS K12 and BLIS M18, which are oral probiotics providing protection for ear, nose and throat health, halitosis (bad breath), gums and teeth health and immune support. The firm distributes its products through Stratum Nutrition in North America, NZPR Group in China, and Bluestone Pharma in Europe and Middle East. Its other BLIS branded products include Throat Guard EVERYDAY BLIS K12, Travel Guard BLIS K12, Fresh Breath Kit K12 and Toddler Protect BLIS K12 Powder for Toddlers.

BLT Intrinsic Value
0.01 NZD
Overvaluation 34%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.9%
=
Operating Profit
1.6m
/
Revenue
12.7m
What is the Operating Margin of BLIS Technologies Ltd?

Based on BLIS Technologies Ltd's most recent financial statements, the company has Operating Margin of 12.9%.